Carrying the Likelihood-of-Approval Flag

Jun 20, 2018 | News

Recent research on clinical trial success rates that caught our eye: We are especially encouraged to see a group from MIT carrying forward the torch of drug likelihood-of-approval (LOA) analysis. That group of researchers put together this great analysis of what they...

Fail Early, Fail Fast – And Increase Likelihood-of-Approval

Feb 10, 2017 | News

What is this saying “Fail Early, Fail Fast” all about? Is there any merit to it and how is this changing the game for all pharmaceutical drug development companies? Here we will give our thoughts and opinions into how this really carries over to the real world and how...

Biomarkers and The Adoption Cycle: Where are we now?

Oct 31, 2016 | Biomarkers, News

This week we introduced the correlation between a company’s biomarker coverage in their clinical trial pipeline and their Likelihood of Approval. After showing correlation between approval and biomarker use, we wanted to know more about a company’s biomarker use...

Companion Diagnostics Play a Confusing Role with PD-1 Inhibitors

May 31, 2016 | News

  There are now three approved drugs that target PD-1 either directly or indirectly, and more are under development.While these drugs all seek to inhibit PD-1’s immune suppressive activity, they are quite different in the ways that companion diagnostic tests play...